The course of infection tends to be more serious in children who are immunocompromised, such as those undergoing chemotherapy or those who have a disease that disrupts normal immune response (e.g. human immunodeficiency syndrome [HIV]).
In older adolescents, common fears include anxiety about school achievement, social rejection and related worries, and sexual anxieties, including dating and sexually transmitted diseases, especially human immunodeficiency virus (HIV).
If a child is known to have an immunodeficiency disorder, a healthcare provider should be contacted if the child shows signs of having an infection, such as fever, vomiting, diarrhea, swelling of the lymph nodes, or unusual fatigue.
Parents who already have a child with hyper-IgM syndrome or who come from families with a history of primary immunodeficiency disorders may wish to consider genetic counseling and prenatal genetic testing with future pregnancies.
As of 2004 no specific treatment cured common variable immunodeficiency; each child is treated according to the individual clinical condition, the symptoms presented, and the antibody subclasses shown to be absent or deficient.
However, someone with a congenital immunodeficiency disorder might want to consider getting genetic counseling before having children in order to find out if there is a chance they will pass the defect on to their children.
Although BMT has been performed on children with severe immunodeficiency disorders since the 1980s, it was usually restricted to those with limited life expectancy because of complications associated with transplantation.
The congenital immunodeficiency disorder, Bruton's agammaglobulinemia, also known as X-linked agammaglobulinemia, results in a decrease or absence of B lymphocytes and, therefore, a decreased ability to make antibodies.
Immune systems may be weakened because of cancer chemotherapy, medications given after organ transplantation, or diseases that significantly lower immune resistance like acquired immunodeficiency syndrome (AIDS).
Common variable immunodeficiency is believed to affect one in 50,000 to 200,000 individuals although it is not always diagnosed, and exact numbers of cases in the population cannot be accurately determined.